Overview and Scope
Human Papillomavirus (HPV) Vaccine refers to a vaccine that aids in preventing specific strains of human papillomavirus (HPV) from infecting the body. HPV vaccines treat most cervical, vaginal, and vulvar cancer occurrences.
Sizing and Forecast
The human papillomavirus (hpv) vaccine market size has grown rapidly in recent years. It will grow from $5.12 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to initial vaccine development, medical guidelines and recommendations, government-sponsored vaccination campaigns, educational initiatives on hpv risks, improvement in vaccine accessibility.
The human papillomavirus (hpv) vaccine market size is expected to see rapid growth in the next few years. It will grow to $9.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to health equity and vaccine equity efforts, inclusion in travel health recommendations, targeted vaccination strategies, pharmaceutical industry investments, telemedicine and remote vaccination.. Major trends in the forecast period include innovation in adjuvant technology, role of hpv vaccination in lgbtq+ health, focus on immunocompromised populations, integration with cancer screening programs, community-based education programs..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report
Segmentation & Regional Insights
The human papillomavirus (hpv) vaccine market covered in this report is segmented –
1) By Type: Tetravalent, Nonavalent, Bivalent
2) By Disease Indication: Cervical Cancer, Anal Cancer, Vulvar And Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Other Indications
3) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels
4) By Industry Vertical: Public And Private Alliance, Government Entities, Physicians, Other Industries
North America was the largest region in the human papillomavirus (HPV) vaccine market in 2023. The regions covered in the human papillomavirus (hpv) vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12040&type=smp
Major Driver Impacting Market Growth
The increased prevalence of HPV-related diseases is expected to propel the growth of the human papillomavirus (HPV) vaccine market going forward. HPV-related diseases are viral infections that frequently result in warts on the skin or mucous membranes. The HPV vaccination specifically targets the HPV subtypes. The HPV vaccine controls the risk of HPV infection and recurrent diseases. For Instance, in February 2023, according to the National Cancer Institute, a US-based Department of Health and Human Services, around 13,960 American women are anticipated to have an aggressive cervical cancer diagnosis, and 4,310 fatalities from this illness are expected in 2023 in the US. Further, 7.7 per 100,000 women per year new cases of cervical cancer were diagnosed, with an annual death rate of 2.2 per 100,000 females. Therefore, the increased prevalence of HPV-related diseases is driving the growth of the human papillomavirus (HPV) vaccine market.
Key Industry Players
Major companies operating in the human papillomavirus (HPV) vaccine market report are Johnson & Johnson Co, Merck & Co Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Pharma Ltd., Astellas Pharma Inc., CSL Limited, UCB SA, Serum Institute of India Pvt Ltd., Beijing Wantai Biological Pharmacy Enterprise Co Ltd., Emergent BioSolutions Inc., Bharat Biotech International Ltd., Walvax Biotechnology Co Ltd., Bavarian Nordic AS, Biofarma Co, Vaccitech PLC, Inovio Pharmaceuticals Inc., R-Pharm LLC, PathoVax LLC
The human papillomavirus (hpv) vaccine market report table of contents includes:
1. Executive Summary
2. Human Papillomavirus (HPV) Vaccine Market Characteristics
3. Human Papillomavirus (HPV) Vaccine Market Trends And Strategies
4. Human Papillomavirus (HPV) Vaccine Market – Macro Economic Scenario
5. Global Human Papillomavirus (HPV) Vaccine Market Size and Growth
.
.
.
31. Human Papillomavirus (HPV) Vaccine Market Other Major And Innovative Companies
32. Global Human Papillomavirus (HPV) Vaccine Market Competitive Benchmarking
33. Global Human Papillomavirus (HPV) Vaccine Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Human Papillomavirus (HPV) Vaccine Market
35. Human Papillomavirus (HPV) Vaccine Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
